Home›Clinical trials›Massachusetts

GLP-1 clinical trials in Massachusetts: 19 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

19 GLP-1 clinical trials are recruiting at 22 sites in 8 cities across Massachusetts. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Massachusetts

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Massachusetts

  2. GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

    Phase 4. Run by Massachusetts General Hospital. Registry number NCT06003153.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with metabolic diseases lower blood sugar.

    Who can join. Adults 18 to 65, have metabolic diseases.

    1 site in Massachusetts

    • Massachusetts General Hospital, Boston. 6176435419

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Massachusetts

    • Metro Boston Clinical Partners, Brighton

  4. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    1 site in Massachusetts

  5. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in Massachusetts

    • Boston Children's Hospital, Boston

  6. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Massachusetts

    • Lucida Clinical Trials, New Bedford

  7. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Massachusetts

    • Lucida Clinical Trials, New Bedford

  8. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in Massachusetts

  9. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in Massachusetts

    • Lucida Clinical Trials, New Bedford

  10. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Massachusetts

  11. Study of Tirzepatide for Recovery and Alcohol Use Management

    Phase 2. Run by Brigham and Women's Hospital. Registry number NCT06727331.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18+, have alcohol use disorder, BMI 23+.

    2 sites in Massachusetts

    • Brigham and Women's Hospital, Boston
    • Brigham and Women's Faulkner Hospital, Jamaica Plain. 617-732-5752

  12. Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

    Phase 2. Run by Massachusetts General Hospital. Registry number NCT05933499.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 27+.

    1 site in Massachusetts

  13. GLP-1R Agonist Treatment for Opioid Use Disorder

    Phase 2. Run by Milton S. Hershey Medical Center. Registry number NCT06548490.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18 to 75, have opioid use disorder, BMI 18+.

    1 site in Massachusetts

    • Stanley Street Treatment and Resources, Fall River. 508-324-3522

  14. Semaglutide for Helping Opioid Recovery

    Phase 2. Run by Brigham and Women's Hospital. Registry number NCT06639464.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder.

    1 site in Massachusetts

  15. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07415954.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Massachusetts

    • Brigham & Women's Hospital, Boston

  16. Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

    Phase 1. Run by Massachusetts General Hospital. Registry number NCT07095517.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with colorectal adenoma.

    Who can join. Adults 18 to 50, have colorectal adenoma, BMI 27+.

    1 site in Massachusetts

    • Massachusetts General Hospital Cancer Center, Boston. 617-726-3212

  17. Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

    Run by Brigham and Women's Hospital. Registry number NCT06069622.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27+.

    1 site in Massachusetts

    • Brigham and Women's Hospital, Boston

  18. Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

    Run by Massachusetts General Hospital. Registry number NCT07226947.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18+, have obesity, BMI 25+.

    1 site in Massachusetts

  19. Lifestyle Change Implementation Research Network at PRC at UMass Chan

    Run by University of Massachusetts, Worcester. Registry number NCT07481305.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18+, BMI 27+.

    1 site in Massachusetts

    • UMass Chan Medical School - Shaw Building, Worcester. 617-828-8093

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.